# Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer

> **NCT03223155** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Chicago** · enrollment: 78 (actual)

## Conditions studied

- Stage IV Small Cell Lung Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **RADIATION:** Stereotactic body radiation therapy

## Key facts

- **NCT ID:** NCT03223155
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-09-07
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03223155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03223155, "Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03223155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*